tiprankstipranks
Advertisement
Advertisement

DE:RGO Stock Latest News

Regeneron price target raised to $796 from $769 at Morgan Stanley
The FlyRegeneron price target raised to $796 from $769 at Morgan Stanley
9h ago
REGN
Regeneron price target lowered to $921 from $925 at Bernstein
PremiumThe Fly
Regeneron price target lowered to $921 from $925 at Bernstein
2d ago
REGN
Regeneron price target raised to $779 from $765 at RBC Capital
PremiumThe Fly
Regeneron price target raised to $779 from $765 at RBC Capital
3d ago
REGN
Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
PremiumThe Fly
Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
8d ago
REGN
Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
PremiumThe Fly
Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
8d ago
REGN
Regeneron price target lowered to $801 from $818 at Truist
PremiumThe FlyRegeneron price target lowered to $801 from $818 at Truist
10d ago
REGN
Regeneron assumed with an Overweight at Piper Sandler
Premium
The Fly
Regeneron assumed with an Overweight at Piper Sandler
11d ago
REGN
Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
Premium
The Fly
Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
18d ago
SNY
REGN
Regeneron price target raised to $825 from $800 at Wells Fargo
PremiumThe Fly
Regeneron price target raised to $825 from $800 at Wells Fargo
22d ago
REGN
Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
22d ago
AMGN
REGN
Amgen price target raised to $390 from $375 at Wells Fargo
PremiumThe Fly
Amgen price target raised to $390 from $375 at Wells Fargo
22d ago
AMGN
REGN
Regeneron says Hansoh shares topline data from Phase 3 trial of olatorepatide
PremiumThe Fly
Regeneron says Hansoh shares topline data from Phase 3 trial of olatorepatide
1M ago
REGN
Regeneron initiated with an Overweight at Barclays
PremiumThe FlyRegeneron initiated with an Overweight at Barclays
1M ago
REGN
Regeneron price target raised to $765 from $745 at RBC Capital
Premium
The Fly
Regeneron price target raised to $765 from $745 at RBC Capital
1M ago
SNY
REGN
Regeneron, Sanofi announces EMA for CHMP adopted positive opinion for Dupixent
Premium
The Fly
Regeneron, Sanofi announces EMA for CHMP adopted positive opinion for Dupixent
1M ago
SNY
REGN
Regeneron, Sanofi announce FDA approval of Dupixent for AFRS
PremiumThe Fly
Regeneron, Sanofi announce FDA approval of Dupixent for AFRS
2M ago
SNY
REGN
Regeneron announces FDA accepted Priority Review for BLA for garetosmab
PremiumThe Fly
Regeneron announces FDA accepted Priority Review for BLA for garetosmab
2M ago
REGN
Regeneron highlights expanding portfolio, pipeline at AAAI
PremiumThe Fly
Regeneron highlights expanding portfolio, pipeline at AAAI
2M ago
SNY
REGN
Regeneron price target raised to $975 from $865 at Guggenheim
PremiumThe Fly
Regeneron price target raised to $975 from $865 at Guggenheim
2M ago
REGN
Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks
PremiumCompany AnnouncementsRegeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks
2M ago
REGN
Regeneron price target raised to $800 from $740 at Cantor Fitzgerald
Premium
The Fly
Regeneron price target raised to $800 from $740 at Cantor Fitzgerald
2M ago
REGN
Regeneron price target raised to $742 from $630 at Baird
Premium
The Fly
Regeneron price target raised to $742 from $630 at Baird
2M ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >